Navigation Links
Cellular Dynamics Announces Presentations at the Society of Toxicology's 52nd Annual Meeting Demonstrating the Expanding Impact of iPSC-Derived Human Cells on Toxicology Assay Development
Date:3/8/2013

MADISON, Wis., March 8, 2013 /PRNewswire/ -- Cellular Dynamics International, Inc. (CDI), a leading commercial producer of human induced pluripotent stem cell (iPSC) lines and tissue cells for drug discovery, safety, stem cell banking and cellular therapeutics, today announced scientific presentations at the Society of Toxicology's 52nd Annual Meeting (SOT), March 10 to 14 in San Antonio, that demonstrate the expanding utility of CDI's iCell® products on toxicology assay development.

"Now that several iPSC-derived human cell types are reliably available in sufficient quantities and at high quality and purity, scientists from academia, government and industry are finding new ways to incorporate them into their toxicology assays," said Chris Parker , chief commercial officer of CDI.  "The scientific data presented at this conference are evidence of the increasing impact that the commercial availability of human cells is having on assay development for toxicity testing and validation of the cells' predictivity."

Researchers will present results on assays that use CDI's iCell Cardiomyocytes, iCell Neurons and iCell Hepatocytes in a variety of toxicology assays, including:

Chantest and ACEA Biosciences detail the use of the xCELLigence Cardio System to evaluate iCell Cardiomyocytes for sensitivity to compounds with broad mechanisms of action. (Exhibitor-hosted sessions, March 11, 9:15 - 10:15 a.m., and 1 - 2 p.m., Room 007B)

LeCluyse, E (The Hamner Institutes for Health Services) provides an overview on iPSC-derived hepatocytes, focusing on their utility in understanding hepatotoxicity mechanisms. (Exhibitor-hosted session, March 13, 1 - 2 p.m., Room 007 B)

Smith, G et al. (Abstract 85, poster 119
'/>"/>

SOURCE Cellular Dynamics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
2. Arteriocyte Receives FDA Approval to Initiate Cellular Therapy Trial for Treatment of Thermal Burn Wounds in Wounded Warriors
3. The Treatment Landscape for Hepatocellular Carcinoma Will Change Dramatically Over the Next Ten Years Due to the Launch of New Therapies in the United States and EU5
4. EastBridge Investment Group Announces Merger with Cellular Biomedicine Group
5. CeeTox and Cellular Dynamics Collaborate to Offer Predictive In Vitro Test for Cardiotoxicity Using Human iPSC-derived Cells
6. Life Technologies and Cellular Dynamics International Partner for Global Commercialization of Novel Stem Cell Technologies
7. Cellular Dynamics Launches MyCell™ Services
8. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of AngioDynamics Inc. in Connection with Executive Compensation
9. Transonic Systems Selects Infinity Info Systems To Implement Microsoft Dynamics CRM To Drive Business Performance And Operational Excellence
10. Zimmer Announces 11% Increase in Quarterly Dividend for First Quarter of 2013
11. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... N.J. , March 27, 2015  Johnson & Johnson ... Shareholders at 10 a.m. (Eastern Time) on Thursday, April 23, ... N.J. Investors and other interested parties ... visiting the Company,s website at www.jnj.com and clicking ... from the meeting will be made available a few hours ...
(Date:3/27/2015)... , March 27, 2015  WebMD Health ... source of health information, today announced an ... National Action Plan for Combating Antibiotic-Resistant ... emphasized the urgency and importance of addressing ... and global health.    The WebMD ...
(Date:3/26/2015)... WASHINGTON , March 26, 2015 "Whether ... potentially patients one day." In a single ... and chief scientific officer at Pfizer,s Centers for ... researchers and scientists fueling progress at America,s biopharmaceutical companies. ... to work side-by-side with academia, patient foundations and the ...
Breaking Medicine Technology:Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2
... Results from two prospective, double-blind placebo controlled multi-center ... pooled European efficacy and safety data in patients with ... presented at the American Academy of Neurology,s (AAN) 61st ... by Merz Pharmaceuticals, which plans to file a Biologic ...
... AS, the human antibody,therapeutics company, announced today that ... were presented by its,collaboration partner Peregrine Pharmaceuticals at ... Cancer Research (AACR) 2009 held during April,18 - ... of PGN635 and PGN632,provided further confirmatory evidence that ...
Cached Medicine Technology:Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 2Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 3Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 4Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 5Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies 2
(Date:3/28/2015)... March 28, 2015 Take a bite ... kicks into action. Acids tumble into the stomach, ready ... faulty valve-like structure lets these acids run amok, triggering ... extremely common symptom. More than 60 million Americans have ... examine where heartburn starts, and how it can be ...
(Date:3/28/2015)... 28, 2015 Emergency Medical Care (EMC), ... in Manhattan, recently commemorated its three-year anniversary of being ... In addition to 24-hour urgent care, Emergency Medical Care ... At this time, Emergency Medical Care’s Urgent Care ... chest pain, eye injuries, ear infections, fevers, insect bites, ...
(Date:3/28/2015)... March 28, 2015 Pitching speed, player’s height, ... of shoulder and elbow injuries, according to new research released ... AOSSM ) Specialty Day. , “Our findings indicate that a ... increase in likelihood of a history of injury, a 10 ... 12% increase likelihood of a history of injury, and playing ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 Early ... patients with Type V AC joint injuries, according to ... presented today at the American Orthopaedic Society for Sports ... returned to duty faster when surgery was not performed. ... with 7 receiving surgical treatment and 17 receiving non-surgical ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), ... therapy jobs, has announced that it will participate ... Association Annual Conference to be held April 10-11, ... Columbus, OH. , The OPTA Annual Conference ... products and services. , Representatives from Aureus ...
Breaking Medicine News(10 mins):Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2
... HealthDay Reporter , MONDAY, Nov. 8 (HealthDay News) -- ... must make in order to breast-feed is their sleep. But ... The study, published online Nov. 8 in the journal ... amount of time whether they were breast-feeding or formula-feeding. ...
... The use of statins among a group of postmenopausal ... to the results of a prospective analysis of data from ... results of our study are consistent with the majority of ... among users of statins," said Michael S. Simon, M.D., professor ...
... found that chemicals used to line junk food wrappers ... being ingested by people where they are contributing to ... acids or PFCAs are the breakdown products of chemicals ... ranging from kitchen pans to clothing to food packaging. ...
... (HealthDay News) -- Among certain patients with a history ... Pradaxa (dabigatran) appears to be as effective as the ... German research reveals. Specifically, the new study suggests ... stroke as effectively as warfarin among those facing an ...
... Breast cancer patients are more likely to have joint pain ... cancer, according to a study presented at the American College ... study is one of the first to identify factors that ... from AI therapy. AIs, the standard adjuvant therapy for ...
... an amphibious fish stays alive for up to two months on ... fishonly about an inch or two longthat live in temporary pools ... Florida. During dry seasons when their pools disappear, the fish hole ... stay moist, they can survive for extended periods out of water ...
Cached Medicine News:Health News: Breast-Feeding Won't Rob Mom of Sleep: Study 2Health News: Breast-Feeding Won't Rob Mom of Sleep: Study 3Health News:Statins did not reduce colorectal cancer in WHI analysis 2Health News:Dangerous chemicals in food wrappers likely migrating to humans: U of T study 2Health News:New Drug, Pradaxa, May Prevent Second Stroke in Certain Heart Patients 2Health News:New Drug, Pradaxa, May Prevent Second Stroke in Certain Heart Patients 3Health News:Study sheds light on aromatase inhibitor joint pain syndrome 2Health News:Study sheds light on aromatase inhibitor joint pain syndrome 3Health News:Special skin keeps fish species alive on land 2
Angled 45 degree shafts with 10.5 mm tying and 1 mm of tip crisscross serrated. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.2 inches....
Straight, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Straight shafts with 6 mm tying platform. Wide serrated handle with polished finish. Overall length 4.3 inches. Overall length 4.3 inches....
Curved shafts and tips with 6.5 mm tying platform. Flat serrated handle with dull finish. Overall length 3.9 inches. Overall length 3.9 inches....
Medicine Products: